Kiniksa Pharmaceuticals International, plc

KNSA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001730430

A

strongest fifth of 369 graded peers in healthcare

rank 4 of 369; percentile 0.8; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	B	percentile 23.3
Solvency	B	percentile 33.2
Growth and financing	A	percentile 11.8
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $763.6M
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: dilution, distress, fortress balance sheet
Inputs computable	8 of 14	
Graded from	filings received through Feb 24, 2026	250 days before the rescan; latest periodic filing 10-Q received Oct 27, 2026
Last close	$92.12	2026-10-30; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1? ("IL-1?") and interleukin-1? ("IL-1?") cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 23.3						
Gross profitability	78.6%	32.4%		9.9	366	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(11.8%)	(6.6%)		36.7	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						
Solvency, sleeve percentile 33.2						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2026-09-30						
Altman Z double-prime	5.08	(0.35)		18.6	748	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	3.79x	2.92x		47.7	829	2025-12-31
Growth and financing, sleeve percentile 11.8						
Revenue growth, three-year compound	45.5%	10.1%		14.8	412	2025-12-31
Free cash flow growth, three-year compound	188.1%	10.9%		1.1	96	2025-12-31
Reinvestment rate	308.5%	37.1%		8.7	104	2025-12-31
Asset growth, three years	18.4%	2.2%		22.4	696	2025-12-31
Net share issuance, one year	not computable	2.5%				
two annual share counts are required; found 0						

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
1	Protagonist Therapeutics, Inc. (PTGX)	0.0	A	fortress balance sheet
2	Delcath Systems, Inc. (DCTH)	0.3	A	fortress balance sheet
3	Inspire Medical Systems, Inc. (INSP)	0.5	A	fortress balance sheet
4	Kiniksa Pharmaceuticals International, plc (KNSA)	0.8	A	
5	Mimedx Group, Inc. (MDXG)	1.1	A	fortress balance sheet
6	Harmony Biosciences Holdings, Inc. (HRMY)	1.4	A	fortress balance sheet
7	BeOne Medicines Ltd. (ONC)	1.6	A	fortress balance sheet
8	Progyny, Inc. (PGNY)	1.9	A	
9	Exelixis, Inc. (EXEL)	2.2	A	fortress balance sheet

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	101.6%	(2.2%)	90
Distance from 52-week high	(5.5%)	(28.7%)	83
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.53	(0.19)	90

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$81.7M
Operating cash flow, four quarters	$198.8M
Months of runway	not finite
Days since last periodic filing	5 (10-Q received Oct 27, 2026)
Median daily dollar volume, 63 sessions	$36.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$677.6M	2025-12-31	2026-02-24	10-K	26-019168
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$77.7M	2025-12-31	2026-02-24	10-K	26-019168
3	assets	us-gaap:Assets	$763.6M	2025-12-31	2026-02-24	10-K	26-019168
4	net income	us-gaap:NetIncomeLoss	$59.0M	2025-12-31	2026-02-24	10-K	26-019168
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$138.0M	2025-12-31	2026-02-24	10-K	26-019168
6	assets	us-gaap:Assets	$580.6M	2024-12-31	2026-02-24	10-K	26-019168
7	current assets	us-gaap:AssetsCurrent	$527.2M	2025-12-31	2026-02-24	10-K	26-019168
8	current liabilities	us-gaap:LiabilitiesCurrent	$139.2M	2025-12-31	2026-02-24	10-K	26-019168
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$462.1M	2025-12-31	2026-02-24	10-K	26-019168
10	operating income	us-gaap:OperatingIncomeLoss	$77.2M	2025-12-31	2026-02-24	10-K	26-019168
11	book equity	us-gaap:StockholdersEquity	$567.6M	2025-12-31	2026-02-24	10-K	26-019168
12	liabilities	us-gaap:Liabilities	$196.0M	2025-12-31	2026-02-24	10-K	26-019168
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$423.2M	2024-12-31	2026-02-24	10-K	26-019168
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$270.3M	2023-12-31	2026-02-24	10-K	26-019168
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$220.2M	2022-12-31	2025-02-25	10-K	25-001505
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.6M	2025-12-31	2026-02-24	10-K	26-019168
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$25.7M	2024-12-31	2026-02-24	10-K	26-019168
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$277,000	2024-12-31	2026-02-24	10-K	26-019168
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$13.3M	2023-12-31	2026-02-24	10-K	26-019168
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$130,000	2023-12-31	2026-02-24	10-K	26-019168
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.8M	2022-12-31	2025-02-25	10-K	25-001505
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$105,000	2022-12-31	2025-02-25	10-K	25-001505
23	depreciation amortization	us-gaap:Depreciation	$196,000	2025-12-31	2026-02-24	10-K	26-019168
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$88.9M	2025-12-31	2026-02-24	10-K	26-019168
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$29.9M	2025-12-31	2026-02-24	10-K	26-019168
26	current assets	us-gaap:AssetsCurrent	$331.8M	2024-12-31	2026-02-24	10-K	26-019168
27	current liabilities	us-gaap:LiabilitiesCurrent	$100.6M	2024-12-31	2026-02-24	10-K	26-019168

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	assets	us-gaap:Assets	$526.3M	2023-12-31	2025-02-25	10-K	25-001505
29	assets	us-gaap:Assets	$459.7M	2022-12-31	2024-02-28	10-K	24-002005